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Abstract 
Background: Advances in research suggest the possibility of improving routine clinical care for preeclampsia using 
screening (predictive) and diagnostic tests. The views of women should be incorporated into the way in which such 
tests are used. Therefore, we explored the views of women with experience of preeclampsia and other hypertensive 
disorders in pregnancy (HDPs) about predictive and diagnostic tests, treatment risks, and expectant management.
Method: Eight hundred and seven women with experience of preeclampsia or other HDPs completed an online 
questionnaire. These women were participants in the Preeclampsia Registry (USA). The questionnaire contained 
22 items to elicit women’s views about predictive tests (n = 8); diagnostic tests (n = 5); treatment risks (n = 7), and 
expectant management (n = 2). An optional text box allowed participants to add qualitative open-ended comments. 
Levels of agreement with the statements were reported descriptively for the sample as a whole, and a preliminary 
investigation of the role of lived experience in shaping women’s views was conducted by comparing subgroups 
within the sample based on time of HDP delivery (preterm/term). The qualitative data provided in the optional text 
box was analysed using inductive thematic analysis to examine participants’ responses.
Results: Women generally favored predictive and diagnostic testing, although not because they would opt for 
termination of pregnancy. Participants generally disagreed that taking daily low-dose aspirin (LDA) would make them 
nervous, with disagreement significantly higher in the preterm delivery subgroup. A high proportion of participants, 
especially in the preterm delivery subgroup, would take LDA throughout pregnancy. The majority of participants 
would be more worried about the possibility of preeclampsia than about the risks of treatments to their health (60%), 
and that proportion was significantly higher in the preterm delivery subgroup. There were no differences between 
subgroups in the views expressed about expectant management, although opinion was divided in both groups. 
Overall, most participants opted to put the baby’s interests first.
Conclusion: Women with experience of hypertensive disorders were enthusiastic about improved predictive and 
diagnostic tests. However, varied views about treatment options and expectant management suggest the need for 
a shared decision-making tool to enable healthcare professionals to support pregnant women’s decision-making to 
maximize the utility of these tests and interventions.
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Background
Preeclampsia, a leading cause of maternal and fetal mor-
bidity and mortality, causes approximately 42,000 deaths 
worldwide annually and complicates 2–8% of pregnancies 
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[1, 2]. Characterised by hypertension and multi-organ 
dysfunction, preeclampsia can also be complicated by 
fetal growth restriction and preterm birth [3, 4]. Effective 
treatment for preeclampsia is delivery, regardless of ges-
tational age, which will not always prevent or ameliorate 
postpartum preeclampsia [4, 5]. A history of preeclamp-
sia raises risk of preeclampsia in subsequent pregnancies 
and risk of cardiovascular disease in subsequent years 
above that of women with normotensive pregnancy his-
tory [6]. Prophylactic low-dose aspirin (LDA) lowers the 
risk of developing preterm preeclampsia [7].
Although early identification of women at risk ena-
bles timely management [1], diagnosis of preeclampsia 
is reliant on blood pressure readings, quantification of 
proteinuria and bloodwork, and nonspecific symptoms 
(e.g. headache) indicative of severe features. Variation 
in onset, clinical presentation, and severity affect the 
specificity and reliability of clinical assessments, making 
screening and diagnosis challenging [1, 8].
Advances in research suggest the possibility of improv-
ing routine clinical care using screening (predictive) and 
diagnostic tests [9–12]. Such tests would be valuable 
for the management of the mother and baby, so may be 
implemented in the future. Maternal and fetal interests 
may conflict when pregnant women have to make ear-
lier decisions about care. Implementation of these tests 
should be based on their acceptance by the target popula-
tion. However, there is a paucity of literature on women’s 
views and decision aids on this topic.
Furthermore, although research suggests that women 
with hypertensive disorders beyond 37 weeks gestation 
would benefit from planned delivery [13], a March of 
Dimes public education campaign emphasizes that “39 
weeks is worth the wait” to reduce elective inductions. 
These messages may affect women’s perceptions on the 
timing of delivery.
Resolving these dilemmas requires understanding 
women’s views about predictive and diagnostic tests, and 
how these affect decisions about treatment, and early 
delivery. There is an increasing focus on decision aids 
to guide communications and shared decision-making 
[14], and maternal-fetal health organizations’ education 
and support of women. This study explored the views 
of a convenience sample of women with experience of 
hypertensive disorders in pregnancy (HDPs) about tests, 
treatment risks, and expectant management to guide 
development of consumer messages and education cam-
paigns, and inform future research.
Methods
An online self-completion questionnaire was developed 
and piloted through multiple iterations by the Preec-
lampsia Foundation, clinicians, and social scientists. 
Questions addressed dilemmas and drew on phrasing 
advanced by women with histories of HDPs. Survey 
participants were informed that tests and treatments 
were not necessarily available to patients, “preeclamp-
sia” was described to include most HDPs, and defini-
tions of screening and diagnostic tests were provided. 
The questionnaire contained demographic and clinical 
history questions, and 22 items designed to elicit par-
ticipants’ views about: predictive tests (n = 8), diagnostic 
tests (n = 5), treatment (n = 7), and expectant manage-
ment (n = 2). To minimize acquiescence response bias, 
both positively and negatively framed questions were 
included [15]. Participants rated each item on a six-point 
Likert scale ranging from Strongly Disagree to Strongly 
Agree. An optional text box allowed participants to 
add comments. For the full questionnaire, please see 
Additional file 1.
Participants and procedure
Data collection was carried out by the Preeclamp-
sia Foundation, Florida, USA, via https:// www. preec 
lamps iareg istry. org. Initially, Preeclampsia Registry 
members were recruited through Preeclampsia Foun-
dation communications, web searches, and social 
media. Informed consent was obtained on-line from 
all members willing to participate, and they then com-
pleted a questionnaire to self-report health history, 
diagnosis of a hypertensive disorder, and pregnancy 
outcomes. (A previous Preeclampsia Registry study 
showed that 181 (94.3%) of 192 participants accurately 
recalled their pregnancy diagnosis [16].) Three thou-
sand, five hundred and fifty eight women reporting a 
history of an HDP were invited by email to complete 
the Your Point of View questionnaire. Eight hundred 
and sixty one participants started the questionnaire 
and 807 completed it between October 2016 and July 
2019. There were no significant differences in baseline 
demographics between women responding and those 
not responding (see Table 1). Data analysis was explor-
atory, investigating the views of a convenience sample 
of women to inform future research.
All the experiment protocol for involving humans 
was in accordance to guidelines of the Declaration of 
Helsinki. Study protocols regarding human subjects 
were approved by the Advarra Institutional Review 
Board (IRB), a private independent IRB (https:// www. 
advar ra. com/).
Analysis
Responses were reported descriptively for the sample 
as a whole, and a preliminary investigation of the role 
of experience in shaping women’s views was conducted 
by comparing pre-term and term delivery subgroups, 
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because this distinction is of major importance for clini-
cal care, reliably reported, and both categories are well 
represented numerically within the study sample. This 
distinction is of major importance in the emerging lit-
erature on prediction and prevention. A skewed distribu-
tion of scores was found for the majority of items, so the 
six-point Likert scales were collapsed into the binary cat-
egories ‘Agree’ and ‘Disagree’. The proportion of women 
agreeing with each statement was compared between 
subgroups using chi-square. A stringent significance level 
(< 0.001) was adopted in light of the exploratory nature of 
the analysis.
The qualitative data provided in the text box was ana-
lysed using inductive thematic analysis to explore partici-
pants’ responses.
Results
The final sample consisted of 807 participants from the 
United States (84%), Canada (5%), United Kingdom (4%) 
and other countries (7%) (see Table 1).
Views about predictive tests
Women generally favored these, and there were no differ-
ences between subgroups (see Table 2).
Table 1 Demographic information and pregnancy outcomes for participants (n = 807) and non-responders (n = 2697)
a n = 457 participants and n = 1260 non-respondents. bn = 796 participants and n = 2686 non-respondents. In some cases (n=7) the maximum reported SBP and DBP 







  Caucasian 771 (95.5) 2453 (91.0)
  Black 18 (2.2) 81 (3.0)
  Native American 13 (1.6) 63 (2.3)
  Asian 6 (0.7) 63 (2.3)
  Pacific Islander 4 (0.5) 8 (0.3)
  Asian Indian 1 (0.1) 13 (0.5)
 One or more preterm HDP deliveries (< 37 weeks) 545 (67.5) 1873 (69.4)
At time of first HDP pregnancy
 Maternal age at delivery (years), mean +/− SD 30.5+/−6.0 29.2+/−5.2
 Years since pregnancy at start of survey 5.7+/−7.5 8.2+/− 7.3
 Nulliparity 726 (90.0) 2441 (90.5)
 Assisted Reproductive Technology 84 (10.4) 224 (8.3)
 Started prenatal care- Less than 12 weeks 774 (95.9) 2284 (84.7)
 Multiple gestation 32 (4.0) 106 (3.9)
 Elevated liver enzymes 469 (58.1) 1202 (44.6)
 Kidney problems 131 (16.2) 452 (16.8)
 Low platelet count 357 (44.2) 945 (35)
 Fluid in lungs 77 (9.5) 202 (7.5)
 Seizure 49 (6.1) 113 (4.2)
 Increased protein 579 (71.7) 1719 (63.7)
 aMaximum systolic blood pressure (mm Hg), mean +/− SD 181+/−24.9 184+/− 26.7
 aMaximum diastolic blood pressure (mm Hg), mean +/− SD 111+/− 17.9 112+/− 19.3
 Postpartum depression 115 (14.3) 336 (12.5)
Birth beyond 20 weeks, 1st HDP Pregnancy
 Birthweight (g), mean +/−SDb 2198.9 +/− 1003.1 2142.6+/− 995.6
 Gestational age at delivery (weeks), mean +/−SD 34.1 +/− 4.7 33.8 +/− 4.6
 Cesarean delivery 526 (63.3) 1517 (54.3)
 Male fetal sex 415 (49.9) 1388 (49.6)
 Female fetal sex 391 (47.1) 1359 (48.6)
 Fetal/infant demise 90 (10.8) 318 (11.4)
 Baby admitted to the NICU 424 (51.0) 1294 (46.3)
 Length of stay in NICU (days), mean +/−SD 31.2 +/−  34.3 32.0 +/− 37.8
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Most participants wanted to use a predictive test in 
early pregnancy, even if it were not 100% accurate (94%), 
and a similar proportion (95%) disagreed with want-
ing a predictive test to consider early termination. A 
clear majority agreed that the availability of a test would 
have led to different choices in pregnancy management 
(79%). On anxiety, most agreed that a prediction of low 
risk would enable them to be more relaxed about their 
prenatal care (69%) though not inclined to skip appoint-
ments, and a greater proportion thought that a predictive 
test would give them some peace of mind (81%); how-
ever, when asked directly if a predictive test would add to 
their anxiety, about half (55%) agreed that it would. Most 
agreed a predictive test would be useful even though ‘we 
don’t have a ‘cure’ for preeclampsia’ (97%), and that they 
would be willing to pay a modest fee for an accurate pre-
dictive test (88%).
Participants’ qualitative responses show that they value 
predictive tests because a high-risk result could enable 
earlier access to care:
“There is a desperate need for more testing for Preec-
lampsia. Doctors say they know the signs, yet most 
women who have experienced very severe cases have 
been managed poorly.” (Preterm)
Some participants thought that an inaccurate low-risk 
result could lead to care delays:
“…a prediction test that shows a low risk might make 
some doctors delay treatment of Pre-eclampsia, …
because a "test" claimed the risk was low.” (Preterm)
Views about diagnostic tests
Views about the value of diagnostic tests were gener-
ally positive and did not vary between subgroups (see 
Table 3).
Most participants (77%) disagreed that current diag-
nostic methods are sufficient. A greater proportion 
agreed that a diagnostic test would give them some peace 
of mind (95%), be useful to them even though there is no 
cure (99%), and was so important that they would be will-
ing to pay a modest fee (92%). As with predictive tests, 
opinion was more divided as to whether a diagnostic test 
would add to anxiety, but the majority said that it would 
not (67%).
Qualitative responses suggest participants believed 
current diagnostic procedures were inadequate and diag-
nostic tests would be valued because standardized results 
could prompt speedy, accurate management:
“There needs to be a common, consistent, univer-
sal tool …I developed preeclampsia both times, but 
they had different requirements on when it was truly 
"preeclampsia" and not pregnancy induced hyper-
tension.” (Preterm)
Views about preventive treatment
On this topic, participants who had had a preterm deliv-
ery held significantly different views from the term 
Table 2 Participants’ views about prediction tests (All comparisons non-significant)




n % n %
1. Even if a prediction test were not 100% accurate, I would want to take a test early in my pregnancy that lets me 
know my chances of developing a problem like preeclampsia.
Agree 515 94.5 243 92.7
Disagree 30 5.5 19 7.3
2. If a simple blood test that predicted if I would get preeclampsia had been available during my previous 
pregnancy(ies), we probably would have made different choices in the management of my pregnancy.
Agree 444 81.5 202 77.1
Disagree 101 18.5 60 22.9
3. If a prediction test were available that would tell me in my first trimester that I will most likely get preeclampsia, 
I would consider terminating my pregnancy.
Agree 30 5.5 10 3.8
Disagree 515 94.5 252 96.2
4. If a prediction test showed my risk to develop preeclampsia was low, I would be more relaxed about my prena-
tal care.
Agree 370 67.9 180 68.7
Disagree 175 32.1 82 31.3
5. A test to predict if I might get preeclampsia at a later stage during pregnancy would give me some peace of 
mind.
Agree 445 81.7 217 82.
Disagree 100 18.3 45 17.2
6. A test to predict if I might get preeclampsia at a later stage during pregnancy would add to my anxiety. Agree 301 55.2 143 54.6
Disagree 244 44.8 119 45.4
7. A test to predict if I might get preeclampsia at a later stage during pregnancy would be useful to me even 
though we don’t have a “cure” for preeclampsia.
Agree 526 96.5 253 96.6
Disagree 19 3.5 9 3.4
8. An accurate prediction test that tells me if I will get preeclampsia is so important that even if it was not 
included in my healthcare coverage, I would be willing to pay a modest amount out of pocket for it.
Agree 488 89.5 222 84.7
Disagree 57 10.5 40 15.3
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delivery subgroup, on three of the seven items (see 
Table 4).
Participants, especially in the preterm subgroup, disa-
greed with feeling nervous about taking daily LDA to 
reduce their risk of developing preeclampsia without 
certainty that there were no developmental effects on the 
fetus (64%). Overall, the majority of participants agreed 
they would be willing to take LDA throughout pregnancy 
because it has been shown in some studies to safely 
decrease some women’s risk (92%), with willingness sig-
nificantly higher in the preterm subgroup.
Most participants would be willing to participate in a 
research study to test medication that has been shown to 
be safe for infants, but has not yet been used by pregnant 
women, if it may prevent preeclampsia (77%). Also, most 
participants agreed they would be more concerned with 
the safety of any treatment to their fetus’s health than 
their own health (91%).
Most participants would be willing to consider treat-
ments with side effects to reduce their preeclampsia 
risk (82%) and to change their diet, even though there 
are no studies to prove that diet affects risk (92%). How-
ever, when asked to compare risks to themselves from 
experimental treatments, views were more divided and 
the strength of opinion differed between the subgroups: 
overall most participants would be more worried about 
Table 3 Participants’ views about diagnostic tests (All comparisons non-significant)




n % n %
9. Current methods for diagnosing preeclampsia are sufficient. Agree 133 24.4 57 21.8
Disagree 412 75.6 205 78.2
10. A test to diagnose preeclampsia during pregnancy would give me some peace of mind. Agree 516 94.7 250 95.4
Disagree 29 5.3 12 4.6
11. A test to diagnose preeclampsia during pregnancy would add to my anxiety. Agree 182 33.4 85 32.4
Disagree 363 66.6 177 67.6
12. A test to diagnose preeclampsia during pregnancy would be useful to me even though we don’t have a “cure” 
for preeclampsia.
Agree 538 98.7 259 98.9
Disagree 7 1.3 3 1.1
13. An accurate diagnostic test that tells me if I have preeclampsia is so important that even if it was not included 
in my healthcare coverage, I would be willing to pay a modest amount out of pocket for it.
Agree 500 91.7 245 93.5
Disagree 45 8.3 17 6.5
Table 4 Participants’ views about treatment for HDPs





n % n %
14. I would feel nervous taking one baby aspirin per day to reduce my risk of developing preeclampsia 
without being sure that there were no effects on my baby many years later.
Agree 175 32.1 119 45.4 .0002
Disagree 370 67.9 143 54.6
15. Even though there are no studies to prove that a woman’s diet is related to getting preeclampsia, I 
would be willing to significantly change my diet to try to reduce my risk.
Agree 506 92. 243 92.7 ns
Disagree 39 7.2 19 7.3
16. I would be willing to consider other treatments with possible side effects in order to reduce my 
chance of getting preeclampsia.
Agree 450 82.6 205 78.2 ns
Disagree 95 17.4 57 21.8
17. Because baby aspirin has been shown in some studies to safely decrease some women’s risk of 
developing preeclampsia, I would be willing to take it throughout pregnancy even if it may not help 
me at all.
Agree 516 94.7 228 87.0 .00015
Disagree 29 5.3 34 13.0
18. I would be willing to participate in a research study to test a medication that has been shown to be 
safe for the baby, but has not yet been used by pregnant women, if it may help prevent preeclampsia.
Agree 433 79.4 187 71.4 ns
Disagree 112 20.6 75 28.6
19. When thinking about experimental treatments to prevent preeclampsia, I am more worried about 
the possibility of getting preeclampsia than I am about the risks of those treatments to my health.
Agree 365 67.0 144 55.0 .0009
Disagree 180 33.0 118 45.0
20. When thinking about possible treatments to improve my pregnancy outcomes, I am more con-
cerned with the safety of the treatment to my unborn baby’s health than I am to my health.
Agree 500 91.7 236 90.1 ns
Disagree 45 8.3 26 9.9
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preeclampsia than about the risks of those treatments to 
their health (60%), and that proportion was significantly 
higher in the preterm delivery subgroup (Table 4).
Some participants expressed concerns about lack of 
information on the risks of LDA:
“I’m not sure I would [take aspirin] during pregnancy 
unless the data showed that it was safe.” (Term)
Views about expectant management
There were no differences between the subgroups in their 
views about expectant management (Table  5), although 
opinion was divided within groups.
The majority of participants opted to put the baby’s 
interests first, although this varied between considering 
that it was better to deliver as soon as possible (66%), and 
aiming to stay pregnant as long as possible for the per-
ceived benefits to the baby (73%).
In their qualitative responses, most participants’ con-
cerns related to the challenge of decision-making about 
delivery timing, given the implications for health and/or 
survival of mother and baby:
"Trying to balance my own health needs with those 
of my unborn baby was the most trying part... The 
mommy guilt was, and still is, incredible... but so 
was my desire to stay alive. " (Preterm)
Participants explained they would delay delivery to 
increase their baby’s chance of survival, even if this 
resulted in “serious implications” for their own health. 
However, many participants also understood that delay-
ing delivery meant increased risks for the baby:
"My baby was not delivered early enough and he was 
stillborn, so I lean toward delivery ASAP but not for 
my own health… to avoid losing another child." (Pre-
term)
Views about delivery timing were also related to partici-
pants’ desire to minimize the baby’s time in a neonatal 
intensive care unit:
"Every day in the womb exponentially reduces the 
time an infant spends in the NICU (neonatal inten-
sive care unit)." (Preterm)
Other participants expressed a preference for early deliv-
ery because of the adverse implications of delay for the 
mother’s health:
"…There are too many terrible complications that 
can result after birth for the mother… early delivery 
is vital." (Term)
Participants explained that the decision was also about 
the risk of leaving their children motherless:
"I am not willing to die to give my baby extra time 
and leave him or her, my husband, and other chil-
dren alone. … if death is on the table, I would choose 
to save mine…" (Term)
Participants clarified the difficulty in choosing between 
their own and their baby’s survival, and the need to sup-
port women to prioritize their own health:
"…Special attention and advocacy needs to be paid 
to the mother because she will never worry about 
herself first before her baby unless she has adequate 
information that her own life could be at risk." (Pre-
term)
Many participants expressed their trust in doctors to 
support decision-making based on their expertise:
"…I’d want to defer a great deal to my doctor’s guid-
ance, because frankly they have medical training 
and I do not." (Term)
However, other participants lacked confidence in doctors 
because of their experiences and perceptions of incompe-
tence in recognizing and managing the condition:
"Doctors say they know the signs, yet most women 
who have experienced very severe cases have been 
managed poorly. I have very little confidence in the 
doctors who managed me as a patient." (Preterm)
Table 5 Participants’ views about expectant management (both comparisons non-significant)
Question Response Preterm (n = 545) Term (n = 262)
n % n %
21. If I am diagnosed with severe preeclampsia, I am uncom-
fortable with doctors trying to evaluate when to deliver the 
baby to “buy time.” It is better to deliver as soon as possible.
Agree 169 31.0 103 39.3
Disagree 376 69.0 159 60.7
22. If I reached a point where I had to choose, I would rather 
see how long I could stay pregnant – even if this causes me to 
face some risks to my own health – rather than risk my baby 
being born too early.
Agree 401 73.6 187 71.4
Disagree 144 26.4 75 28.6
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Discussion
Participants had high levels of interest in predictive and 
diagnostic tests, irrespective of personal experience of a 
preterm delivery. Participants acknowledged the positive 
aspects of such testing, valuing knowledge of enhanced 
risk to improve pregnancy management, with very few 
who would undertake testing to consider termination. 
Participants also favored LDA for the prevention of 
HDPs, and the preterm subgroup particularly supported 
participation in research into therapeutics. Although 
women with preterm pre-eclampsia may have had higher 
rates of maternal and perinatal complications compared 
to those with term deliveries, responses to the question-
naire were similar from both groups of women across the 
majority of responses, suggesting that the presence of the 
disease is a bigger determinant than gestation at delivery. 
Overall, participants had varied views about expectant 
management and planned delivery, and there was no sin-
gle preferred course of action. Our findings suggest that 
women want better predictive and diagnostic tests, and 
that their acceptance of risk is likely to vary depending on 
the severity of their experiences of HDPs.
Improved predictive and diagnostic tests can enable 
planned delivery, reducing maternal morbidity [17]. 
Similar to other studies, participants valued predic-
tive and screening tests because of earlier access to 
care [18, 19]. Support for informed decisions should 
include information about how such tests relate to bet-
ter expectant management and improved pregnancy 
outcomes [20]. While approximately half of the par-
ticipants believed a predictive test would add to their 
anxiety, women’s potential anxiety may be less notable 
in clinical practice than our results suggest since their 
other perspectives suggest high support for predictive 
tests, and arguably benefits will outweigh risks when 
women are well-supported.
Similar to other studies [21], our participants favored 
preventive measures to reduce risk, including use of LDA 
- particularly those in the preterm subgroup. For preec-
lampsia prevention, LDA is currently the only drug for 
which there is evidence of benefit [22]. Given our partici-
pants’ acceptance of preventive aspirin and the support-
ing clinical literature, HDP screening programs should 
include LDA for women screening positive, with infor-
mation on the implication of this treatment while still 
emphasizing continued vigilance for signs and symptoms 
of HDP [23]. Participants’ concerns about the implica-
tions of treatment on their fetus highlight the need for 
adequate information to facilitate informed consent [21].
Participants’ views varied most about delivery timing. 
This may be due to their differing experiences of HDP, 
perceived implications for other family members, and 
understanding of the implications of different options. 
Women trade off possible benefits and harms, doing so 
in uncertain circumstances. There is some research on 
women’s experience of preeclampsia [24], but little on 
how they make decisions about care. A shared decision-
making tool for HDPs could enable women to make 
informed decisions in better accordance with their own 
values. Women’s views are integral to improving mater-
nity care; the development of such a tool requires further 
exploration of women’s experiences, expectations and 
values using more in-depth qualitative methodologies 
[24, 25].
A predictive test for preeclampsia must be offered early 
in pregnancy to all women. The literature shows that risk 
stratification based on maternal factors and pregnancy 
history is insufficient. The efficacy of LDA has been 
shown to be greater if treatment is begun early. Knowing 
that taking LDA is likely to be beneficial because the cur-
rent pregnancy is at elevated risk may increase women’s 
willingness to follow a drug regimen.
Any benefits of treatment are less clear for women not 
classed at higher risk, and there may be downsides to 
classification: people identified as ‘low risk’ may be less 
prepared to take precautionary steps or to be vigilant for 
signs and symptoms of HDP, and, since no screening test 
is perfect, false reassurance of women and care providers 
will need to be guarded against.
Once diagnosed, women need to be given up-to-date 
information on the risks of different courses of action, 
and subsequent management must take account of the 
differing preferences expressed. Since these circum-
stances are often highly charged, urgent medical crises, 
education and decision-making tools must be deliber-
ately kept straightforward.
The information needs of the general pregnant popula-
tion about tests for HDPs require further investigation, as 
does the best way of communicating ‘elevated risk’. Better 
understanding is needed of how various factors (demo-
graphics, pregnancy and neonatal unit experience, etc.) 
influence attitudes to care.
More representative samples and studies using dif-
ferent methods to assess attitudes would be desirable, 
including the effects of different phrasing and the ways 
that trade-offs are presented. The relevance and role of 
anxiety in screening and treatment decisions is unclear 
[26, 27].
Women already weigh complex, morally-charged ‘com-
peting risks’. The use of a decision aid for those facing 
dilemmas needs investigation, based on a current under-
standing of women’s information needs and of factors 
affecting test uptake and treatment compliance in differ-
ent subgroups.
Future comparisons between ‘screen-and-treat’ strate-
gies and other approaches to reducing the incidence and 
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harms of HDPs need to integrate the role of women’s 
beliefs, attitudes and behavior as mediators of prevention 
and treatment.
Strengths and limitations
A strength of our study is that it demonstrates women’s 
important but neglected role in the research on pre-
eclampsia. Limitations include that the convenience 
sample from the Preeclampsia Registry is not representa-
tive of the wider population of pregnant women, and the 
response rate (22%) will also have introduced bias. Fur-
ther studies are needed on, samples which include partic-
ipants from previously under-represented groups. Also, 
similar research in a normotensive population could have 
enhanced the findings, but recruiting such participants 
would have been challenging because of their lack of 
knowledge or motivation to support research for an unfa-
miliar condition.
The survey provided clear, consistent evidence of con-
sensus on some topics, e.g., the value of predictive/diag-
nostic tests, and diversity of views on others, especially 
those entailing the weighing of different risks. On some 
topics the wording of questions seemed to influence lev-
els of agreement, but it is unclear whether this reflected 
genuinely nuanced views, or other differences in ques-
tion content or wording. Only a minority of questions, all 
on the topic of prevention, led to differences of opinion 
between preterm or term subgroups.
The exploratory statistical analysis was confined to a 
set of simple comparisons. A more comprehensive mod-
elling exercise could make use of the finer-grained atti-
tude information captured in the Likert scales and the 
additional details in the Preeclampsia Registry dataset.
Conclusion
Predictive and diagnostic tests and treatments would be 
valued by women with experience of HDPs. However, 
varied views about management suggest the need for 
shared decision-making and educational tools.
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